Letter Agreement, dated February 10, 2023, between the Company and May Orfali, M.D
Exhibit 10.24
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO SIGILON THERAPEUTICS, INC. IF PUBLICLY DISCLOSED.
February 10, 2023
BY HAND & ELECTRONIC DELIVERY
May Orfali, M.D.
Dear May:
As we have discussed, your employment with Sigilon Therapeutics, Inc. (the “Company”) has terminated, effective as of February 10, 2023 (the “Separation Date”), and you will transition to a consulting role. The purpose of this letter (the “Agreement”) is to confirm the terms concerning your separation, as follows:
Formalities aside, I want to take this opportunity to thank you for all of your efforts on behalf of the Company and to wish you well in your future endeavors.
Sincerely,
SIGILON THERAPEUTICS, INC.
By:/s/ Rogerio Vivaldi
Rogerio Vivaldi Coelho, M.D., MBA
President and Chief Executive Officer
Accepted and agreed:
Signature:/s/ May Orfali
May Orfali, M.D.
Date: 2/24/2023
Consulting Agreement
[May Orfali, MD, MBA]
This Consulting Agreement (the “Agreement”), is made as of February 14, 2023 (the “Effective Date”) by and between Sigilon Therapeutics, Inc. (the “Company”), with offices at 100 Binney Street, Suite 600, Cambridge, MA 02142, and Rare Disease and Oncology Consulting, LLC/ May Orfali, MD, MBA (the “Consultant”).
In consideration of the mutual covenants and promises contained herein and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged by the parties hereto, the parties agree as follows:
[Signature page follows.]
IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.
SIGILON THERAPEUTICS, INC. | CONSULTANT |
| |
By:/s/ Rogerio Vivaldi | By: /s/ May Orfali |
Print Name: Rogerio Vivaldi | Print Name: May Orfali |
Title: President, CEO | Title: President |
Date: February 14, 2023 | Date: February 14, 2023 |
Note to Consultant
Please return a completed IRS Form W-9 to ***@*** to enable payment.
Schedule A
Description of Services
The Consultant will provide services to the Company relating to the following:
[***]